Shionogi Inc.’s Osphena (ospemifene) may offer an alternative to estrogen therapy for treatment of pain during sexual intercourse in postmenopausal women that carries a lower risk of blood clots.
FDA approved Osphena Feb. 26 to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?